Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (13)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Yokel, R. A.
Right arrow Articles by McNamara, P. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yokel, R. A.
Right arrow Articles by McNamara, P. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Toxicological Sciences 64, 77-82 (2001)
Copyright © 2001 by the Society of Toxicology

NEUROTOXICOLOGY

Entry, Half-Life, and Desferrioxamine-Accelerated Clearance of Brain Aluminum after a Single 26Al Exposure

Robert A. Yokel*,{dagger},1, Susan S. Rhineheimer*, Pankaj Sharma{ddagger}, David Elmore{ddagger} and Patrick J. McNamara*,{dagger}

* College of Pharmacy and {dagger} Graduate Center for Toxicology, University of Kentucky Medical Center, Lexington, Kentucky 40536-0082; and {ddagger} Purdue Rare Isotope Measurement Laboratory, Department of Physics, Purdue University, West Lafayette, Indiana 47907

The objectives of our study were to estimate the percentage of aluminum (Al) that enters the brain, the half-life of brain Al, and the ability of an Al chelator to reduce brain Al. Rats received an iv infusion of Al transferrin, the primary Al species in plasma, or Al citrate, the predominant small molecular weight Al species in plasma. The infusion contained ~ 0.2–0.3 nCi (0.4–0.6 nmol) 26Al, enabling the study of Al distribution into and retention by the brain at physiological Al concentrations. Some Al transferrin–infused rats received ip injections of the Al chelator desferrioxamine (DFO), 0.15 mmol/kg, three times weekly. The others received saline injections. The rats were euthanized from 4 hr to 4 days (Al citrate) or 256 days (Al transferrin) later. Brain 26Al was determined by accelerator mass spectrometry. Peak brain 26Al concentration was ~ 0.005% of the 26Al dose in each gram of brain, irrespective of Al species administered. In the absence of DFO treatments, brain 26Al concentration decreased with a half-life of approximately 150 days. The brain Al half-life in the DFO-treated rats was approximately 55 days. The results show a small fraction of Al in blood enters the brain, where it persists for a long time. The ability of repeated DFO treatments to modestly accelerate the reduction of brain Al is consistent with the necessity of prolonged DFO therapy to significantly reduce Al-induced dialysis encephalopathy.

Key Words: accelerator mass spectrometry; aluminum; brain; chelation therapy; desferrioxamine; half-life; rat.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum Exp ToxicolHome page
S. Kim, J. Nam, and K. Kim
Aluminum exposure decreases dopamine D1 and D2 receptor expression in mouse brain
Human and Experimental Toxicology, September 1, 2007; 26(9): 741 - 746.
[Abstract] [PDF]

Home page
 Toxicol SciHome page
V. S. Silva, A. I. Duarte, A. C. Rego, C. R. Oliveira, and P. P. Goncalves
Effect of Chronic Exposure to Aluminium on Isoform Expression and Activity of Rat (Na+/K+)ATPase
Toxicol. Sci., December 1, 2005; 88(2): 485 - 494.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.